Next Article in Journal
Screening for Colorectal Cancer Leading into a New Decade: The “Roaring ‘20s” for Epigenetic Biomarkers?
Previous Article in Journal
Novel Therapeutic Method for Unresectable Pancreatic Cancer—The Impact of the Long-Term Research in Therapeutic Effect of High-Intensity Focused Ultrasound (HIFU) Therapy
Article

What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience

1
Department of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
2
1st Department of Obstetrics and Gynecology, Alexandra Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(6), 4862-4873; https://doi.org/10.3390/curroncol28060410
Received: 4 September 2021 / Revised: 9 November 2021 / Accepted: 17 November 2021 / Published: 20 November 2021
(This article belongs to the Section Gynecologic Oncology)
Uterine serous carcinoma accounts for 3–10% of endometrial cancers, but it is the most lethal histopathological subtype. The molecular characterization of endometrial carcinomas has allowed novel therapeutic approaches for these patients. We undertook a retrospective analysis of patients with uterine serous carcinomas treated in our hospital within the last two decades to identify possible changes in their management. The patients and their characteristics were evenly distributed across the two decades. Treatment modalities did not change significantly throughout this period. After adjuvant treatment, patients’ median disease-free survival was 42.07 months (95% CI: 20.28–63.85), and it did not differ significantly between the two decades (p = 0.059). The median overall survival was 47.51 months (95% Cl: 32.18–62.83), and it significantly favored the first decade’s patients (p = 0.024). In patients with de novo metastatic or recurrent disease, median progression-free survival was 7.8 months (95% Cl: 5.81–9.93), whereas both the median progression-free survival and the median overall survival of these patients did not show any significant improvement during the examined time period. Overall, the results of our study explore the minor changes in respect of uterine serous carcinoma’s treatment over the last two decades, which are reflected in the survival outcomes of these patients and consequently underline the critical need for therapeutic advances in the near future. View Full-Text
Keywords: cancer; endometrial; p53 abnormal expression; survival cancer; endometrial; p53 abnormal expression; survival
Show Figures

Figure 1

MDPI and ACS Style

Liontos, M.; Svarna, A.; Theofanakis, C.; Fiste, O.; Andrikopoulou, A.; Kaparelou, M.; Koutsoukos, K.; Thomakos, N.; Haidopoulos, D.; Rodolakis, A.; Dimopoulos, M.A.; Zagouri, F. What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. Curr. Oncol. 2021, 28, 4862-4873. https://doi.org/10.3390/curroncol28060410

AMA Style

Liontos M, Svarna A, Theofanakis C, Fiste O, Andrikopoulou A, Kaparelou M, Koutsoukos K, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Zagouri F. What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience. Current Oncology. 2021; 28(6):4862-4873. https://doi.org/10.3390/curroncol28060410

Chicago/Turabian Style

Liontos, Michalis, Anna Svarna, Charalampos Theofanakis, Oraianthi Fiste, Angeliki Andrikopoulou, Maria Kaparelou, Konstantinos Koutsoukos, Nikolaos Thomakos, Dimitrios Haidopoulos, Alexandros Rodolakis, Meletios A. Dimopoulos, and Flora Zagouri. 2021. "What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience" Current Oncology 28, no. 6: 4862-4873. https://doi.org/10.3390/curroncol28060410

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop